Targeted Strategies for Today's Evolving Markets

MissionIR Blog

MissionIRNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM), BayMedica Slated to Participate in Tribe Public Webinar

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing and clinical development of rare cannabinoids, has announced that its CEO Eric A. Adams will be a featured presenter at Tribe Public’s upcoming complimentary ZOOM presentation titled “Accelerating The Commercialization of Rare Cannabinoids.” The webinar is scheduled to begin on Sept. 21, 2021, at 11.30 a.m. ET. In addition to Adams, BayMedica Inc. cofounder Shane Johnson will also present during the event. Adams and Johnson’s presentation will be hosted by Tribe Public managing member John F. Heerdink Jr., who will field live questions and pass those on to the presenters. In addition, registered participants can send questions prior to the webinar. Earlier this month, InMed announced a definitive agreement to acquire BayMedica, a strategic move that would establish InMed as a global leader in the manufacturing of rare cannabinoids. INM plans to combine its proprietary cannabinoid manufacturing process, IntegraSyn(TM), with BayMedica’s synthetic biology and chemical synthesis capabilities. This combination will enable InMed complete manufacturing flexibility to select the most appropriate, cost-effective method based on the target cannabinoid and appropriate quality specifications for the desired market segment.

To register for the webinar, visit https://ibn.fm/8o0FR

To view the full press release, visit https://ibn.fm/mIMq8

About InMed Pharmaceuticals Inc.

InMed Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of cannabinoid-based pharmaceutical drug candidates, initially focused on the therapeutic benefits of cannabinol (“CBN”); the company is developing IntegraSyn(TM) to produce pharmaceutical-grade cannabinoids. INM is dedicated to delivering new therapeutic alternatives to patients who may benefit from cannabinoid-based medicines. For more information, please visit www.InMedPharma.com.  

NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

This entry was posted in InMed Pharmaceuticals Inc. INM. Bookmark the permalink.

Comments are closed.